R-ketamine (Arketamine)
Unlike the S enantiomer, the FDA has not given approval to Arketamine as an antidepressant–yet. However, there are both promising preclinical research and open-label trials showing Arketamine may be superior for severe depression. Arketamine shows weaker activity at the NMDA and sigma receptors. As a result, it produces fewer hallucinogenic and dissociative effects than ketamine.
Reviews
There are no reviews yet.